Paul C, et al. - Researchers compared the safety and effectiveness of ixekizumab, an IL-17A antagonist, vs the IL-12/23 inhibitor, ustekinumab, through 52 weeks of treatment in the head-to-head trial, IXORA-S. Compared to ustekinumab, ixekizumab showed superior efficacy and comparable safety outcomes through 52 weeks of treatment. More frequently, the injection site reactions occurred in the ixekizumab treatment group. No difference was noted in TEAE, serious AEs, and discontinuation rates between the treatment groups.